Journal Article Reports New Data Regarding Administration of Quadramet(R) (Samarium Sm-153 Lexidronam Injection) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Quadramet represents part of a multi-disciplinary medical approach enabling medical oncologists, radiation oncologists and nuclear medicine physicians to manage pain from metastatic bone disease
PRINCETON, NJ — January 25, 2007 — Cytogen Corporation today reported the publication of a study by independent investigators evaluating the safety and efficacy of Quadramet(R) (samarium Sm-153 lexidronam injection) in combination […]